EK-DRD

EK-DRD provides experimentally validated annotations for FDA-approved and withdrawn small-molecule drugs to support systematic drug repositioning and identification of new therapeutic uses.

Key Features:

• Content scope: Annotations for 1,861 FDA-approved and 102 withdrawn small-molecule drugs.
• Annotation levels: Target assay records (30,944), cell assay records (3,999), organism assay records (585), and clinical trial records (8,889).
• Curation methods: Annotations obtained through text and data mining techniques complemented by manual curation.
• Integration: Links approximately 1,799 repositioning protein or target sequences with 856 related diseases and 1,332 pathways.
• Search modalities: Supports text, sequence, chemical structure, and relational queries.

Scientific Applications:

• Drug repositioning discovery: Enables identification of new therapeutic uses for existing drugs by integrating assay, target, disease, and pathway data.
• Target–disease association analysis: Facilitates exploration of relationships among repositioning protein/target sequences and associated diseases.
• Pathway and network analysis: Supports exploration of drug-target-pathway relationships and complex biological networks to identify novel therapeutic targets and disease associations.

Methodology:

Annotations were curated using text and data mining techniques complemented by manual curation.